News

Stockhead1d
Dr Boreham’s Crucible: Can Sofdra become the ‘world’s most successful dermatology drug?’
Three months after the US Sofdra launch, prescriptions have exceeded Botanix Pharmaceuticals' expectations. What are they ...
Influencer Quenlin Blackwell Uses Breast Milk as Skin Care — Here's What a Dermatologist Thinks of the Trend (Exclusive)
Quenlin Blackwell revealed that she uses breast milk from her sister as part of her skincare routine. Dr. Naana Boakye tells ...
The Manila Times4d
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...
The Manila Times4d
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...
European Medical Journal5d
Understanding Childhood Factors in Atopic Dermatitis Development
Discover a study that found that children with early AD were more likely to develop food allergies, whereas those with later ...
Six 'leg and skin' signs of vitamin D deficiency - including 'symptom sitting in chair'
One of the early signs of vitamin D deficiency is excessive sweating. It is often an overlooked sign. Excessive sweating, ...
PharmiWeb6d
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results
Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss ...
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results
Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss impr ...